top of page
Browse by category
Search
FDA reviewing ProSomnus’ EVO medical device for severe OSA
The FDA has accepted, and is in the process of reviewing, the ProSomnus’ premarket notification for its ProSomnus EVO precision medical...
FDA approves USGI Medical’s pivotal study of the POSE2.0 procedure for primary obesity
The FDA has approved an USGI Medical’s Investigational Device Exemption application to conduct a pivotal study of its POSE2.0...
Roche enters weight loss and metabolic market with Carmot Therapeutics acquisition
Roche has completed its acquisition of Carmot Therapeutics, which includes Carmot’s R&D portfolio including all clinical and pre-clinical...
Lilly receives UK marketing authorisation for tirzepatide (Mounjaro) in alternative Kwikpen presentation for two indications
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Eli Lilly’s tirzepatide...
First NHS patients treated with Allurion Balloon for weight loss
Allurion Technologies has announced that the Somerset NHS Foundation Trust is the first NHS trust in the UK - and the first non-private...
Bariatric Solutions International becomes the exclusive distributor of the Endoscopic Hernia Multifeed Stapler
Bariatric Solutions International (BSI) has signed an agreement with Waston Medical to become the exclusive distributor of the Endoscopic...
Teleflex’ Titan SGS Stapler available with GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement
Teleflex’ Titan SGS Stapler, which according to the company is the only purpose-built stapler for gastric tissue with a specific...
FDA approves ReShape Lifesciences’ next-generation Lap-Band 2.0 FLEX
The FDA has granted approval of a PMA supplement for ReShape Lifesciences’ next generation, enhanced Lap-Band 2.0 FLEX. According to the...
USGI Medical completes Pilot Study of the POSE2.0 incisionless weight loss procedure
The FDA has acknowledged the successful completion of a pilot study of USGI Medical’s incisionless, endoscopic gastroplasty procedure,...
Skye to develop nimacimab for the treatment of obesity by targeting the endocannabinoid system
Skye Bioscience, a pharmaceutical company developing drugs targeting the endocannabinoid system (ECS), has announced that it plans to...
Browse by tag
bottom of page